Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05286242 · ClinicalTrials.gov registry record
Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients
A clinical trial of Multiple Sclerosis and Autoimmune Blistering Disease, sponsored by Yale University.
- Active
- Registry status
- 400
- Enrollment target
- 1
- Study location
NCT05286242: Active study of Multiple Sclerosis and Autoimmune Blistering Disease, sponsored by Yale University.
NCT05286242 is a study of Multiple Sclerosis and Autoimmune Blistering Disease that is active but no longer recruiting, run by Yale University. The registered enrollment target is 400 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05286242, a study of Multiple Sclerosis and Autoimmune Blistering Disease, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand the immune response to coronavirus disease-19 (COVID-19) vaccination in patients on B-cell depleting therapies (BCDT) over time, which in the future may help to inform clinical decision making in this patient population.
Primary Outcome
COVID 19 spike and neutralizing antibody titers will be monitored serially
Conditions Studied
Interventions
- BIOLOGICAL COVID19 vaccine
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2021-02-10 |
| Est. Completion | 2026-06-30 |
What the registry record for NCT05286242 still lists
NCT05286242 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (32% lower).
The record links to 3 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which COVID19 vaccine is the first listed.
NCT05286242 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05286242 about?
NCT05286242 is a clinical study titled "Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients". The purpose of this study is to understand the immune response to coronavirus disease-19 (COVID-19) vaccination in patients on B-cell depleting therapies (BCDT) over time, which in the future may help to inform clinical decision making in this patient population.
What is the current status of trial NCT05286242?
This trial is currently active not recruiting. The enrollment target is 400 participants. The study started on 2021-02-10. Estimated completion is 2026-06-30.
What conditions does trial NCT05286242 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Autoimmune Blistering Disease, B-Cell Deficiency.
What interventions are being tested in trial NCT05286242?
The interventions under investigation include: COVID19 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05286242?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05286242 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05286242's enrollment target sits among peer trials
400 47th of 315 higher than 267 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI